Catalyst Pharmaceutical CPRX Balance Sheet Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $755.86M+30.2% | $709.17M+37.0% | $689.89M+56.0% | $652.8M+73.8% | $580.66M+87.1% | ||
| $130.83M+83.6% | $126.48M+93.2% | $106.41M+82.6% | $65.86M+15.2% | $71.27M+17.8% | ||
| $34.93M+76.6% | $37.17M+90.2% | $28.03M+40.0% | $18.65M+3.5% | $19.78M-0.9% | ||
| $18.77M+33.9% | $21.22M+0.8% | $28.12M+53.0% | $21.43M-9.0% | $14.02M+2.0% | ||
| $940.39M+37.1% | $894.03M+43.4% | $852.45M+58.2% | $758.74M+59.9% | $685.72M+69.5% | ||
| $994K-19.8% | $1.04M-23.4% | $1.08M-22.0% | $1.15M-6.4% | $1.24M-5.3% | ||
| $1.86M-13.9% | $1.94M-13.2% | $2.01M-12.6% | $2.08M-12.1% | $2.16M-11.6% | ||
| $121.97M-17.2% | $131.67M-16.0% | $128.64M-22.5% | $137.98M-21.3% | $147.33M-20.2% | ||
| $55.11M+14.3% | $52.77M+14.8% | $48.26M-0.4% | $50.7M+27.1% | $48.22M+26.0% | ||
| $27.29M+12.7% | $22.54M+4.5% | $19.17M+29.1% | $21.26M+62.5% | $24.21M— | ||
| $1.15B+26.3% | $1.1B+29.7% | $1.05B+36.2% | $971.92M+37.6% | $908.87M+40.5% | ||
| $7.15M-36.1% | $11.2M-32.5% | $9.1M-21.3% | $5.53M-22.3% | $11.2M+9.1% | ||
| $125.25M+24.7% | $135.95M+30.6% | $119.64M+27.5% | $107.48M+26.1% | $100.45M+44.9% | ||
| $446K+8.8% | $437K+8.7% | $428K+8.9% | $419K+8.8% | $410K+8.8% | ||
| $132.4M+18.6% | $147.15M+21.9% | $128.74M+22.1% | $113.01M+22.4% | $111.65M+40.3% | ||
| $2.24M-16.6% | $2.35M-15.6% | $2.46M-14.8% | $2.57M-14.0% | $2.68M-13.3% | ||
| $0— | $0— | $0— | $0— | $0— | ||
| $2.68M-13.3% | $2.79M-12.6% | $2.89M-12.0% | $2.99M-11.4% | $3.09M-10.9% | ||
| $0— | $0— | $0— | $0— | $0— | ||
| $280K+8.1% | $209K-33.7% | $161K-94.2% | $309K-87.1% | $259K-90.1% | ||
| $134.91M+17.7% | $149.71M+21.0% | $131.36M+18.3% | $115.89M+18.6% | $114.59M+34.4% | ||
| $0— | $0— | $0— | $0— | $0— | ||
| $122K0.0% | $123K+1.7% | $123K+3.4% | $122K+2.5% | $122K+3.4% | ||
| $489.22M+8.2% | $479.96M+8.5% | $473.33M+9.7% | $461.87M+9.1% | $452.28M+8.5% | ||
| $523.35M+53.1% | $474.19M+66.3% | $446.79M+94.9% | $394.01M+113% | $341.9M+137% | ||
| $8K+147% | $0-100% | $0— | $31K— | -$17K— | ||
| $1.01B+27.5% | $954.27M+31.1% | $920.25M+39.2% | $856.03M+40.6% | $794.28M+41.5% | ||
| $1.15B+26.3% | $1.1B+29.7% | $1.05B+36.2% | $971.92M+37.6% | $908.87M+40.5% | ||
| $27.29M+12.7% | $22.54M+4.5% | $19.17M+29.1% | $21.26M+62.5% | $24.21M— | ||
| $27.29M+12.7% | $22.54M+4.5% | $19.17M+29.1% | $21.26M+62.5% | $24.21M— | ||
| $1.86M-13.9% | $1.94M-13.2% | $2.01M-12.6% | $2.08M-12.1% | $2.16M-11.6% | ||
| $55.11M+14.3% | $52.77M+14.8% | $48.26M-0.4% | $50.7M+27.1% | $48.22M+26.0% | ||
| $121.97M-17.2% | $131.67M-16.0% | $128.64M-22.5% | $137.98M-21.3% | $147.33M-20.2% | ||
| $1.86M-13.9% | $1.94M-13.2% | $2.01M-12.6% | $2.08M-12.1% | $2.16M-11.6% | ||
| $1.86M-13.9% | $1.94M-13.2% | $2.01M-12.6% | $2.08M-12.1% | $2.16M-11.6% | ||
| $125.25M+24.7% | $135.95M+30.6% | $119.64M+27.5% | $107.48M+26.1% | $100.45M+44.9% | ||
| $125.25M+24.7% | $135.95M+30.6% | $119.64M+27.5% | $107.48M+26.1% | $100.45M+44.9% | ||
| $2.68M-13.3% | $2.79M-12.6% | $2.89M-12.0% | $2.99M-11.4% | $3.09M-10.9% | ||
| $122K0.0% | $123K+1.7% | $123K+3.4% | $122K+2.5% | $122K+3.4% | ||
| $0— | $0— | $0— | $0— | $0— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Can Catalyst Pharmaceutical cover its short-term obligations?
- Its current ratio is 7.10 — current assets exceed current liabilities.
- Where does Catalyst Pharmaceutical's balance sheet data come from?
- Every line is extracted from Catalyst Pharmaceutical's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.